Values First Advisors Inc. Decreases Stock Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

Values First Advisors Inc. trimmed its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 18.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 28,498 shares of the company’s stock after selling 6,382 shares during the period. Values First Advisors Inc.’s holdings in Elanco Animal Health were worth $345,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of ELAN. JPMorgan Chase & Co. raised its position in Elanco Animal Health by 76.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 10,057,656 shares of the company’s stock valued at $147,747,000 after purchasing an additional 4,361,799 shares during the last quarter. State Street Corp grew its position in shares of Elanco Animal Health by 2.6% in the 3rd quarter. State Street Corp now owns 9,912,693 shares of the company’s stock worth $145,617,000 after buying an additional 255,084 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Elanco Animal Health by 0.8% during the third quarter. Geode Capital Management LLC now owns 7,868,675 shares of the company’s stock valued at $115,623,000 after buying an additional 65,303 shares during the period. The Manufacturers Life Insurance Company raised its holdings in shares of Elanco Animal Health by 6.6% during the third quarter. The Manufacturers Life Insurance Company now owns 6,385,467 shares of the company’s stock valued at $93,803,000 after acquiring an additional 394,921 shares in the last quarter. Finally, Wellington Management Group LLP lifted its stake in Elanco Animal Health by 19.2% in the third quarter. Wellington Management Group LLP now owns 4,007,805 shares of the company’s stock worth $58,875,000 after acquiring an additional 646,522 shares during the period. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have issued reports on ELAN. Barclays boosted their price objective on shares of Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, November 8th. Leerink Partners began coverage on shares of Elanco Animal Health in a research report on Monday, December 2nd. They set a “market perform” rating and a $14.00 price target on the stock. UBS Group began coverage on shares of Elanco Animal Health in a research note on Monday, December 9th. They issued a “buy” rating and a $18.00 price target for the company. Morgan Stanley cut their price objective on Elanco Animal Health from $15.00 to $14.00 and set an “equal weight” rating on the stock in a research report on Wednesday, January 29th. Finally, Leerink Partnrs raised Elanco Animal Health to a “hold” rating in a research report on Monday, December 2nd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, Elanco Animal Health has an average rating of “Hold” and a consensus price target of $16.29.

Elanco Animal Health Stock Down 0.3 %

NYSE:ELAN opened at $11.38 on Thursday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The firm has a market cap of $5.63 billion, a P/E ratio of 28.45, a P/E/G ratio of 2.69 and a beta of 1.42. Elanco Animal Health Incorporated has a fifty-two week low of $11.11 and a fifty-two week high of $18.80. The firm has a 50-day simple moving average of $11.97 and a two-hundred day simple moving average of $13.17.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.